Scandion Oncology – Interim Report Q1 2022
Scandion Oncology (Scandion) today announces its interim report for Q1 2022. The following is taken from the report.Bo Rode Hansen, President and CEO, comments “It is with pleasure that we report on our activities for the first quarter of 2022. It has been a good start to the year with solid operations, continued execution of our strategy and implementation of our plans. I am looking at a company “punching above its weight” in several ways.” Key Figures & Highlights TDKK Q1 2022 Q1 2021 FY 2021 Operating loss -16,312 -9,904